CRIS - キュ―リス (Curis Inc.)

CRISのニュース

   Why Curis (CRIS) Shares Are Surging Today?  2021/05/12 16:59:51 Benzinga
Curis Inc (NASDAQ: CRIS ) shares are surging in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). As of data cut off on February 8, in 15 patients (8 MDS and 7 AML), four objective responses were recorded with signs of hematologic recovery, including: One complete response (CR), … Full story available on Benzinga.com
   Point72 Asset Management established new holdings in Curis Inc  2021/04/01 21:30:30 Investing.com
https://www.investing.com/news/stock-market-news/point72-asset-management-established-new-holdings-in-curis-inc-2464353
   Curis Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/03/16 03:35:00 Stock Market Daily
Curis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting  2021/03/10 21:30:00 PR Newswire
LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for…
   Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference  2021/03/02 13:00:00 PR Newswire
LEXINGTON, Mass., March 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company…
   Point72 Asset Management established new holdings in Curis Inc  2021/04/01 21:30:30 Investing.com
https://www.investing.com/news/stock-market-news/point72-asset-management-established-new-holdings-in-curis-inc-2464353
   Curis Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/03/16 03:35:00 Stock Market Daily
Curis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting  2021/03/10 21:30:00 PR Newswire
LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for…
   Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference  2021/03/02 13:00:00 PR Newswire
LEXINGTON, Mass., March 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company…
   Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference  2021/02/19 13:00:00 PR Newswire
LEXINGTON, Mass., Feb. 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company…
   Curis Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/03/16 03:35:00 Stock Market Daily
Curis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting  2021/03/10 21:30:00 PR Newswire
LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for…
   Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference  2021/03/02 13:00:00 PR Newswire
LEXINGTON, Mass., March 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company…
   Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference  2021/02/19 13:00:00 PR Newswire
LEXINGTON, Mass., Feb. 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company…
   Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies  2021/02/09 13:00:00 PR Newswire
LEXINGTON, Mass., Feb. 9, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel,…

calendar